INBX Inhibrx Biosciences, Inc.

NASDAQ
$77.66

Inhibrx Biosciences, Inc. (INBX) is expected to report earnings on February 12, 2027, after the market close. The consensus earnings estimate is a loss of $2.91 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.3% since its last earnings release on November 13, 2026.

Inhibrx Biosciences Beat Consensus Estimates
Friday, November 13, 2026 · 4:02 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 12
Friday · 4:05 PM ET
Earnings Whisper
-
vs ($2.91)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $77.66

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Inhibrx Biosciences, Inc.

Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.